Mazdutide vs Tirzepatide

Molecules and evidence questions

Mazdutide (IBI362; LY3305677) is a GLP-1/glucagon receptor dual agonist. Tirzepatide activates GLP-1 and GIP receptors. The second receptor target is different, but that mechanism does not supply a clinical efficacy or safety ranking. Mazdutide US phase 2 · Mounjaro FDA label

The status row relies on Innovent’s Hong Kong exchange filing, the FDA letter regarding one US mazdutide seller, and the US Mounjaro and Zepbound labels. Innovent is a sponsor source; an independent Chinese product label was not retrieved in this bounded review.

Weight trials: keep controls, populations and timing attached

GLORY-1 enrolled Chinese adults with overweight or obesity, treated for 48 weeks, and used a week-32 primary weight endpoint. GLORY-2 enrolled Chinese adults with obesity, including some with type 2 diabetes. At week 60, GLORY-2 reported mean weight changes of -16.65% for mazdutide 9 mg and -1.50% for placebo among participants who received study treatment. A separate US phase 2 trial enrolled 179 adults without type 2 diabetes and used a 32-week efficacy or hypothetical estimand. These three results are not interchangeable estimates. GLORY-1, PMID 40421736 · GLORY-2, PMID 42251595 · US phase 2, PMID 42628555

SURMOUNT-1 randomized adults with obesity or overweight plus a complication without type 2 diabetes to tirzepatide or placebo and evaluated weight at week 72. The Zepbound label also describes a separate study in adults with type 2 diabetes. Those are within-tirzepatide comparisons, not a trial against mazdutide. A difference between a SURMOUNT percentage and a GLORY percentage is not an estimated treatment difference: geography, entry criteria, follow-up, dose and statistical estimands vary. SURMOUNT-1, PMID 35658024 · Zepbound label, clinical studies

Diabetes and cardiovascular outcomes are separate questions

Chinese DREAMS-1 tested mazdutide against placebo in type 2 diabetes; DREAMS-2 tested it against dulaglutide. Neither directly compared with tirzepatide. SURPASS-CVOT instead studied tirzepatide against dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It found noninferiority for its composite cardiovascular outcome, not a head-to-head cardiovascular benefit over mazdutide. Mounjaro’s US label includes a cardiovascular risk-reduction indication in specified adults with type 2 diabetes at high risk; that approved product claim cannot be transferred to mazdutide. DREAMS-1, PMID 41407859 · DREAMS-2, PMID 41407860 · SURPASS-CVOT, PMID 41406444 · Mounjaro label

Regulatory and safety limits

Mounjaro’s US label covers glycemic control in adults and children aged 10 years or older with type 2 diabetes, plus reduction of major adverse cardiovascular events in specified high-risk adults with type 2 diabetes. Zepbound’s separate US label covers long-term weight reduction for qualifying adults and moderate-to-severe obstructive sleep apnea in adults with obesity. These are product- and population-specific indications. The Zepbound label advises against coadministration with another tirzepatide product or any GLP-1 receptor agonist; no mazdutide-plus-tirzepatide efficacy or safety conclusion follows from the separate trials. Mounjaro label · Zepbound label

Both programs report gastrointestinal adverse events, but differing study designs and ascertainment prevent a reliable cross-trial rate ranking. Tirzepatide’s US labels carry a boxed warning about thyroid C-cell tumors in rodents and a contraindication for a personal or family history of medullary thyroid carcinoma or MEN2. Mazdutide does not have an FDA product label from which to infer equivalent wording or event frequencies. GLORY-2, PMID 42251595 · Mounjaro label

This comparison is educational research context, not medical advice or a treatment protocol.